ImpediMed Surges with Record Revenue and Expanding Reimbursement in Q2 FY25

• Record quarterly revenue of A$3.3 million, up from A$2.7 million in Q1 FY25
• Cash receipts hit a record A$3.4 million with net operating cash outflows reduced to A$2.5 million
• Reimbursed covered lives increased to 258.5 million, with 25 states now above 80% reimbursement coverage
• Annual Recurring Revenue (ARR) grew to A$12.5 million, supported by strong contract renewals and price increases